医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Promethera Biosciences: Announcement Regarding Business Activities in Japan

2019年10月31日 PM06:30
このエントリーをはてなブックマークに追加


 

MONT-SAINT-GUIBERT, Belgium & TOKYO

Promethera Biosciences SA (Group), a global innovator in cell-based medicines and liver diseases, announced the foundation of a new branch office in Tokyo, Promethera Biosciences Japan Branch Ltd on May, 2018. Establishing a branch office in Japan marks the starting point for building a strong presence of Promethera in Japan first, initially focusing on increased Business Development, Investor Relations activities and expansion of its business and products pipeline in Japan. This presence will also address the Asian markets as a second step.

As we develop such business activities, we are considering various options for further strengthening our presence in Japan. These options include future listing on the Tokyo Stock Exchange Market (whether or not using a Japanese Depositary Receipt (JDR scheme*) or another Asian stock exchange, and/or partnering with pharmaceuticals.

*for more information of the JDR scheme, please see
https://www.jpx.co.jp/english/equities/listing-on-tse/new/basic/05.html

About Promethera Biosciences:

Promethera Biosciences is a global innovator in liver therapeutics whose mission is to bring life-saving treatments to reduce the need for liver transplantation. Our lead clinical program, derived from our patented cell technology platform HepaStem, is designed to benefit from its immune-modulatory and anti-fibrotic properties. In addition to our cell-based pipeline, we develop antibody technologies such as the antiTNF-R1 antibody Atrosimab, to complement and diversify our therapeutic options. We are a team of international experts operating out of facilities in Mont-Saint-Guibert (Belgium), Durham (NC, USA), Tokyo (Japan) and Basel (Switzerland).

Promethera®, HepaStem®, H2stem®, are all registered trademarks of the PROMETHERA group.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191031005412/en/

CONTACT

Promethera Biosciences Japan Branch

Mutsuki Takano, Group CFO / Masumi Akahori, Senior IR Manager

info.japan@promethera.com

Tel: +81 (0)3-5843-6077

Web: www.promethera.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 武田和Frazier Healthcare Partners宣布合作成立HilleVax, Inc.以开发临床阶段诺如病毒候选疫苗
  • Astellas and Minovia Therapeutics Announce Strategic Collaboration for Novel Mitochondrial Cell Therapy Programs
  • Sports & Health ShopeeMall & LazMall Store, Crazybadman Extends Discounts Indefinitely to Help Combat Surge in Covid-19 Cases
  • 武田薬品工業: 2021年度第1四半期は堅調な業績を達成、トップライン成長およびパイプラインの持続的な推進を加速
  • Takeda Delivers Solid First Quarter FY2021 Results, Positioning Company to Accelerate Topline Growth and Continued Pipeline Progress